key: cord-0754565-3nzjnrde
authors: González-García, Jose Gregorio; Pascual-Guardia, Sergi; Aguilar Colindres, Ricardo J.; Herrero, Pilar Ausín; Miranda, Mariela Alvarado; Guevara, Mariela Arita; Bonet, Diana Badenes; Calduch, Salome Bellido; Caguana Vélez, Oswaldo A.; Gargallo, Cinta Cumpli; Dominguez-Alvarez, Marisol; Gea, Joaquim; Grau, Nuria; Kilhzi, Karys; Martínez-Llorens, Juana; Ortiz, Mónica Sánchez; Sánchez-Font, Albert; Sancho-Muñoz, Antonio; Parrilla-Gómez, Francisco José; Judith, Marín Corral; Terán, Purificación Pérez; Rodríguez-Sevilla, Juan José; Chalela, Roberto; Rodríguez-Chiaradia, Diego
title: Incidence of pulmonary embolism in patients with NON-INVASIVE respiratory support during COVID-19 OUTBREAK
date: 2021-02-04
journal: Respir Med
DOI: 10.1016/j.rmed.2021.106325
sha: 06c19be25cfd7b4b1769ea6ecf773766f341de6c
doc_id: 754565
cord_uid: 3nzjnrde

While the incidence of thrombotic complications in critically ill patients is very high, in patients under non-invasive respiratory support (NIS) is still unknown. The specific incidence of thrombotic events in each of the clinical scenarios within the broad spectrum of severity of COVID-19, is not clearly established, and this has not allowed the implementation of thromboprophylaxis or anticoagulation for routine care in COVID-19. Patients admitted in a semi-critical unit treated initially with NIS, especially Continuous-Positive Airway Pressure (CPAP), were included in the study. The cumulative incidence of pulmonary embolism was analyzed and compared between patients with good response to NIS and patients with clinical deterioration that required orotracheal intubation. 93 patients were included and 16% required mechanical ventilation (MV) after the NIS. The crude cumulative incidence of the PE was 14% (95%, CI 8–22) for all group. In patients that required orotracheal intubation and MV, the cumulative incidence was significantly higher [33% (95%, CI 16-58)] compared to patients that continued with non-invasive support [11% (CI 5-18)] (Log-Rank, p =0.013). Patients that required mechanical ventilation were at higher risk of PE for a HR of 4.3 (95%CI 1.2–16). In conclusion, cumulative incidence of PE is remarkably higher in critically patients with a potential impact in COVID-19 evolution. In this context, patients under NIS are a very high-risk group for developing PE without a clear strategy regarding thromboprophylaxis.

While the incidence of thrombotic complications in critically ill patients is very high, in patients under non-invasive respiratory support (NIS) is still unknown. The specific incidence of thrombotic events in each of the clinical scenarios within the broad spectrum of severity of COVID-19, is not clearly established, and this has not allowed the implementation of thromboprophylaxis or anticoagulation for routine care in COVID-19. Patients admitted in a semi-critical unit treated initially with NIS, especially Continuous-Positive Airway Pressure (CPAP), were included in the study. The cumulative incidence of pulmonary embolism was analyzed and compared between patients with good response to NIS and patients with clinical deterioration that required orotracheal intubation. 93 patients were included and 16% required mechanical ventilation (MV) after the NIS. The crude cumulative incidence of the PE was 14% (95%, for all group. In patients that required orotracheal intubation and MV, the cumulative incidence was significantly higher [33% (95%, CI 16- J o u r n a l P r e -p r o o f INTRODUCTION Several reports have shown that acute respiratory distress syndrome (ARDS) is the most common respiratory complication in patients with severe infection by SARS-CoV-2 and is widely accepted that thrombosis, especially acute pulmonary embolism (PE), is a well-recognized complication of severe COVID-19 (2) . In contrast to findings from ARDS secondary to influenza A (H1N1), SARS-CoV-2 infection induce endothelial injury, widespread vascular thrombosis with microangiopathy, and occlusion of alveolar capillaries with a significant new vessel growth through a mechanism of intussusceptive angiogenesis (3) . Moreover, in patients with severe COVID-19, different grades of coagulopathy associated with disseminated intravascular coagulopathy (DIC) have been observed. In this population, the presentation of the severe disease has a characteristic pattern that include high levels of D-dimer and fibrinogen (4, 5) In line with this, while the incidence of thrombotic complications in critically ill patients is very high, in patients under non-invasive respiratory support (NIS) is still unknown (6, 7) . The specific incidence of thrombotic events in each of the clinical scenarios within the broad spectrum of severity of COVID-19, is not clearly established, and this has not allowed the implementation of thromboprophylaxis or anticoagulation for routine care in COVID-19 (8, 9) . In this context, the purpose of the present study was to investigate the cumulative incidence of PE in COVID-19 patients receiving NIS for respiratory failure during their hospitalization. (BiPAP) and/or High-flow Oxygen Therapy (HFO). We decided on a selected group of patients to treat with NIS, mainly CPAP, as initial treatment, as a bridge to orotracheal intubation or as definitive treatment. In all cases, there was an immediate re-evaluation, to decide if they continued with the NIS or required orotracheal intubation. This strategy has been adopted by various European groups with positive results (10, 11) .

The patients were COVID-19 positive according to the actual diagnostic criterion (12) . All patients with moderate or severe COVID-19 underwent serial D-dimer since it is an accepted marker of prognosis. If there was an elevation of the same along with clinical suspicion of PE based on current guidelines, a multidetector computed tomography pulmonary angiography (CTPA) was performed (13 Table 1 .

The crude cumulative incidence of the PE was 14% (95%, CI 8-22) for all group.

However, in patients that required orotracheal intubation and MV, the cumulative incidence was significantly higher [33% (95%, CI 16-58)] compared to patients that continued with non-invasive support [11% (CI 5-18)] (Log-Rank, p =0.013) (Figure 1 ).

The median days from initial symptoms to PE diagnosis was 21 days (IQR 13-25).

Patients that required mechanical ventilation were at higher risk of PE for a HR of 4. In the patients who a CTPA was performed and the presence of PE was confirmed, the D-dimer was 6.8-fold higher than the patients in whom PE was ruled out (27,076 ng/mL vs 3,943 ng/mL, p=0.002). No differences were found in terms of age, sex or comorbidities, and regarding the biomarkers of severity, the patients who presented clinical worsening after NIS, had only significant differences in levels of CRP. D-dimer was almost the double in patients requiring MV, regardless of whether they presented J o u r n a l P r e -p r o o f PE or not. However, only four patients died, this means a global mortality of 4.3% (no differences were found between both groups). 

Our study in patients with respiratory failure by COVID-19 under NIS has provided three relevant findings. First, the cumulative incidence of PE in our patients under NIS was almost 10-fold higher than in patients in ward according to previous reports (15) .

Second, the cumulative incidence of PE for patients that required orotracheal intubation after the NIS was more than 3-fold higher than patients that responded to initial treatment. Third, our study confirms that patients under mechanical ventilation represent a high-risk group to develop PE during COVID-19 evolution.

The high cumulative incidence of PE in critically ill patients with COVID-19 has been demonstrated during the last months (6, 15) , however the incidence in patients receiving NIS has not been evaluated to our knowledge. The main reasons for the development of thrombotic complications in COVID-19 are uncontrolled inflammatory reaction and coagulopathy in the context of significant endothelial dysfunction (16) . These physiopathological processes are present in all the stages of the disease with special relevance in patients requiring intensive care unit (ICU) (8, 9) . However, up to the present time,

there are no studies clearly identifying patients at high risk in early stages of SARS-

Our results indicate that severity of the disease can be related with the increased incidence of PE but is less clear that thrombotic events play an independent role in the prognosis of patients, or if is a direct consequence of the disease. In line with this, it has been hypothesized that the origin of the increased d-Dimer is intra-alveolar fibrin deposition in the context of severe acute lung injury (17) . Also, our study confirm that CRP is probably the best biomarker to follow-up patients with severe respiratory failure and COVID-19 pneumonia (18, 19) . In our cohort IL6 was elevated in all patients, as expected because all of them had severe disease, but no difference was found between both groups. Finally, hypertension, obesity, dyslipidemia and diabetes were highly J o u r n a l P r e -p r o o f incident among both groups of patients (20) . It is noteworthy that despite analyzing a cohort of patients with severe respiratory disease, where bilateral pneumonia and pulmonary thromboembolism even coexist, more than 40% of patients did not report dyspnea at the time of admission. This finding known as "happy hypoxia" is being debated in the scientific community and has already been described by some groups The current study also has several limitations. In the majority of the patients in whom a CTPA was performed, no other thrombotic complications beyond PE were evaluated.

Although it is possible that thrombotic disease was underestimated, we have evaluated two large homogeneous groups at the same level of severity at the beginning of the study, since they all were under NIS.

In conclusion, cumulative incidence of PE is remarkably higher in critically patients with a potential impact in COVID-19 evolution. In this context, patients under NIS are a very high-risk group for developing PE without a clear strategy regarding thromboprophylaxis.

J o u r n a l P r e -p r o o f

COVID-19): Situation Report -82

Severe Covid-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. Obstetrics, Gynecology and Reproduction

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pulmonary embolism in patients with Covid-19 pneumonia

Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19

Online ahead of print

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal

Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two period retrospective case-control study

World Health Organization. Surveillance strategies for COVID-19 human infection

The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Online ahead of print

Endothelial cell infection and endotheliitis in COVID-19

The source of elevated plasma D-dimer levels in COVID-19 infection

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

The mystery of the pandemic's 'happy hypoxia

The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19